Board of Directors

R. Stephen Beatty is our President and Chief Executive Officer and has served on the Board of Directors since May 1999. Prior to joining the Company, Mr. Beatty established and operated Beatty Finance, Inc., a private financial services company serving the legal profession. Prior to founding Beatty Finance, Inc., Mr. Beatty worked with BellSouth where he managed one of BellSouth’s corporate re-engineering teams, directed the development of enterprise software for BellSouth’s marketing division and was a member of BellSouth’s “Future Thinkers”, an in-house corporate think tank. Mr. Beatty obtained his Bachelor of Science in Mathematics with a minor in Economics from the University of South Alabama in 1975. He obtained his Masters in Business Administration from the University of New Orleans in 1997.

Randall L-W. Caudill, D.Phil., was elected to our board of directors in December 2001. Dr. Caudill is the founder and president of Dunsford Hill Capital Partners, a financial consulting firm serving early-stage health care and technology companies. Dunsford Hill Capital Partners provided financial and management services to the Company in 2000 to 2003. From 1987 to 1997 Dr. Caudill was employed by Prudential Securities where he established and headed the firm’s San Francisco investment banking practice. He also served as head of Prudential’s Mergers and Acquisitions Department and was Co-head of Prudential’s Investment Bank. Dr. Caudill currently serves on the boards of SCOLR Inc. and Ramgen Power Systems, Inc., as well as a number of not-for profit entities. He received a master’s degree in Public and Private Management from Yale University and a doctoral degree from Oxford University where he was a Rhodes Scholar.
Committees: Audit, Governance and Finance

John F. Clifford was elected to our board in August 2007. Mr. Clifford is a consultant in the Aesthetic and Dermatology markets. He was Executive Vice President of Dermatology for Photomedex from March 2005 until June 2006 following its acquisition of ProCyte Corporation. He was President, CEO and Chairman of ProCyte from 1996 until 2005. Before joining ProCyte, Mr. Clifford was the President of Orthofix, Inc. U.S., which acquired American Medical Electronics where he was CEO. From 1989 to 1994, he was employed by Davis and Geck, as Division Vice President. From 1964 to 1989, Mr. Clifford held various sales and marketing positions in Ethicon Inc., and Iolab Corp. both Johnson & Johnson companies. Mr. Clifford holds a B.S. in Economics from Villanova University and a M.B.A. in Finance from Drexel University.
Committees: Marketing

Richard M. Cohen joined our board in December 2005. Mr. Cohen has been the President of Richard M. Cohen Consultants since 1996. Richard M. Cohen Consultants is a financial services consulting company that accepts engagements from public and private companies to assist with their corporate finance and corporate governance needs. In addition, since 2003 Mr. Cohen has served as director of Dune Energy, Inc. a publicly traded company (AMES:DNE) for which he served as Chief Financial Officer from November 2003 to April 2005. Mr. Cohen also served as the Chief Financial Officer of Baseline Oil and Gas Corp. (OTBB:BOGA) a publicly held company with interests in oil/gas investments until August 2007. Mr. Cohen is a Certified Public Accountant (New York State). He received a B.S. from the University of Pennsylvania (Wharton) and a M.B.A. from Stanford University.
Committees: Audit Chairman and Compensation

John C. Fiddes, Ph.D. was appointed to our board of directors in March 2003. He was the Vice President of Research, Health Care from 2003 to 2004 for Genencor International, Inc., a diversified biotechnology company that develops products and services for the bioproducts and health care markets. Dr. Fiddes is the former CEO of Tao Biosciences, LLC, where he served during 2002. From 1994 to 2001 Dr. Fiddes held executive positions at IntraBiotics Pharmaceuticals, Inc., serving as Vice President of Research and Development and subsequently Chief Technical Officer and Vice President of Preclinical Research. Dr. Fiddes also serves on the board of directors for Asilomar Pharmaceuticals, Inc. Dr. Fiddes received his Bachelor of Science Degree in Molecular Biology from the University of Edinburgh, and his Doctorate Degree from King’s College at Cambridge University in 1977. He did postdoctoral research as a Research Fellow at the University of California, San Francisco.
Committees: Compensation and Governance

Jeffrey A. Miller, Ph.D. was appointed to our board in 1999. He is the founder and CEO of two investment companies: NewArc Investments (Est. 1997) manages individual, partnership, and institutional investments, and Capital Markets Research provides research services for investment professionals. Dr. Miller has also advised investors in early stage companies for the last seven years. Before embarking on his investment career, he taught at the University of Wisconsin and did extensive consulting, speaking, and public service work on tax and finance issues for the state of Wisconsin, the city of Milwaukee, and several other municipalities and state commissions. Dr. Miller holds a Ph.D. in Political Science from the University of Michigan. His academic background includes public policy analysis, administrative theory, economics and quantitative modeling.
Committees: Compensation Chairman and Governance Chairman

David O’Connor joined our board in March 2006. Mr. O’Connor has been a consultant with Westfield Consultants Group, an independent business consulting firm since 1998. From 1992 to 1998, Mr. O’Connor was the President and a member of the Board of Directors of Merle Norman Cosmetics International, and prior to that he served as an executive officer of InterCare Medical Group & Emergency Department Physicians Medical Group, Visage Beauté Cosmetics, and Merle Norman Cosmetics, Inc. In addition, Mr. O’Connor served as the Chairman of the Board of Directors of the Robert F. Kennedy Medical Center and as President and a member of the Board of Directors of the Beauty Industry West Trade Association. Mr. O’Connor holds a B.S. from the University of Oregon and an M.H.A. from the University of Southern California.
Committees: Marketing Committee

Barry L. Seidman was appointed to our Board of Directors in November 2004. Mr. Seidman has served as Chairman of the Board of Pax Holding Corporation since May 2001. For the preceding ten years, Mr. Seidman was an independent consultant within the securities industry. In prior years, Mr. Seidman was President and Chief Operating Officer of First Options of Chicago and a Partner of Spear Leeds and Kellogg. He also served in various positions at The Options Clearing Corporation, culminating as First Vice President of National Operations. In the past he has served on the Board of Governors of the Philadelphia Stock Exchange and on the Board of Directors of The Options Clearing Corporation. Mr. Seidman is a graduate of St. John’s University with a B.S. in accounting.
Committees: Compensation

Daniel O. Wilds was elected to our board of directors in December 2002. He is the former President and Chief Executive Officer of SCOLR Pharma, Inc. a biopharmaceutical company focusing on the controlled release of pharmaceuticals and nonprescription supplements. From 1998 until 2003 Mr. Wilds served as President of Northwest Biotherapeutics, Inc. Prior to joining Northwest Biotherapeutics, Mr. Wilds was President and Chief Executive Officer of Shiloov Biotechnologies (USA), Inc., from July 1997 to January 1998. Mr. Wilds holds a B.A. from California State University, Los Angeles and a M.B.A. from Northwestern University.
Committees: Audit, Compensation and Finance